The weight loss drug market is about to change forever. On April 10, 2026, the FDA will decide whether to approve orforglipron — Eli Lilly's once-daily weight loss pill that could make weekly injections obsolete for millions of patients.
If approved, orforglipron would be the first small-molecule oral GLP-1 drug for obesity, joining injectable heavyweights Ozempic (semaglutide) and Mounjaro (tirzepatide) in a market that generated $36.5 billion last year alone.
But which one is actually best for you? Here's how they compare on the numbers that matter.
Head-to-Head Comparison
| Feature | Orforglipron | Ozempic (Semaglutide) | Mounjaro (Tirzepatide) |
|---|---|---|---|
| How you take it | Daily pill | Weekly injection | Weekly injection |
| Weight loss | ~12.4% (72 weeks) | ~14.9% (68 weeks) | ~20.9–22.5% (72 weeks) |
| A1C reduction | 2.2% | 1.8% | 2.4% |
| Fasting required? | No | N/A (injection) | N/A (injection) |
| Refrigeration needed? | No | Yes | Yes |
| FDA approved? | Decision April 10, 2026 | Yes (2017) | Yes (2022) |
| Estimated cost | ~$200/month | ~$900/month (list) | ~$1,060/month (list) |
| Manufacturer | Eli Lilly | Novo Nordisk | Eli Lilly |
Why Orforglipron Changes Everything
The biggest advantage of orforglipron isn't the weight loss numbers — it's the form factor. Unlike Ozempic and Mounjaro, which require weekly self-injections with refrigerated pens, orforglipron is a room-temperature daily pill with no fasting restrictions.
That last point matters more than it sounds. Novo Nordisk already sells an oral semaglutide (Rybelsus), but it requires patients to take it on an empty stomach and wait 30 minutes before eating or drinking. In the landmark ACHIEVE-3 trial published in The Lancet in February 2026, orforglipron crushed Rybelsus head-to-head:
- A1C reduction: 2.2%
- Weight loss: 19.7 lbs (9.2%)
- No food timing restrictions
- No refrigeration needed
- A1C reduction: 1.4%
- Weight loss: 11.0 lbs (5.3%)
- 30-minute fasting window required
- Room temperature storage
"The differences were clinically meaningful. Orforglipron outperformed oral semaglutide on every key endpoint," said Dr. Julio Rosenstock, lead investigator and clinical professor at UT Southwestern.
The Catch: Mounjaro Still Wins on Raw Weight Loss
If maximum weight loss is your primary goal, Mounjaro remains the undisputed champion. At the highest dose (15 mg weekly), tirzepatide has demonstrated 20.9% to 22.5% body weight reduction in clinical trials — nearly double what orforglipron achieves.
The reason is structural. Mounjaro is a dual-agonist that activates both GLP-1 and GIP receptors, giving it a two-pronged mechanism that single-target drugs can't match.
Side Effects: The Tradeoff You Need to Know
All three drugs cause gastrointestinal side effects — nausea, vomiting, and diarrhea are the most common. But the discontinuation rates tell the real story.
In the ACHIEVE-3 trial, 9.7% of orforglipron patients stopped treatment due to GI side effects, compared to just 4.9% for oral semaglutide. That's nearly double the dropout rate.
For injectable Ozempic and Mounjaro, discontinuation rates due to side effects typically range from 4–7%, putting orforglipron at the higher end of the spectrum.
The Cost Factor
This is where orforglipron could genuinely disrupt the market. As a small-molecule drug (not a biologic peptide), it's dramatically cheaper to manufacture.
| Drug | List Price | With Insurance/Discount | Medicare Coverage |
|---|---|---|---|
| Orforglipron | ~$200/month (expected) | TBD | Expected mid-2026 |
| Ozempic | ~$900/month | $0–$150 with savings card | Covered (diabetes only) |
| Mounjaro | ~$1,060/month | $0–$150 with savings card | Covered (diabetes only) |
| Wegovy | ~$1,350/month | $0–$150 with savings card | Limited coverage |
In November 2025, the White House negotiated GLP-1 pricing agreements that brought costs down to $245/month for eligible patients. But orforglipron could undercut even that — Eli Lilly has signaled "disruptive pricing" to capture market share.
Small-molecule drugs also don't require the cold-chain logistics that biologics do, which means no supply shortages like the ones that plagued Ozempic and Mounjaro throughout 2023 and 2024.
Timeline: What Happens Next
Which One Should You Choose?
- Choose orforglipron if: you want a daily pill with no injections, no fasting, and lower cost — and can tolerate potentially stronger GI side effects
- Choose Ozempic if: you prefer a proven, well-established weekly injection with years of real-world safety data and cardiovascular benefits
- Choose Mounjaro if: maximum weight loss is your priority and you don't mind weekly injections — its dual-agonist mechanism delivers the best results
- Orforglipron: not yet approved, higher GI discontinuation rates, less weight loss than injectables
- Ozempic: requires refrigeration, weekly injection, less effective than Mounjaro for weight loss
- Mounjaro: most expensive option, weekly injection, thyroid tumor black box warning
The Bottom Line
Orforglipron isn't going to dethrone Mounjaro on raw efficacy. But that's not the point. For the estimated 42 million Americans with obesity who are needle-averse, insurance-limited, or simply want the convenience of a daily pill, orforglipron could be the drug that finally makes GLP-1 therapy accessible.
With the FDA decision just two weeks away, the answer is almost here.
This article is for informational purposes only and does not constitute medical advice. Consult your healthcare provider before starting or switching any medication.
